

We would like to thank the reviewer for his/her very encouraging comments.

From Reviewer: *This is a very interesting and novel review about a possible protective role of SSRIs use in cardiovascular disease in patients with schizophrenia. Overall, it is well written and deserves publication.*

1. The title gives the impression that hard evidence will be presented in text. This is far from being real because findings from studies are limited and controversial. A better title may be: "SSRIs and Risk....Schizophrenia. A controversial but promising approach".

Answer: We completely agree. The title of our manuscript has been changed accordingly.

2. It should be stressed that the very small number of studies cannot warrant any conclusion. Only hypotheses can be made for either direction (protective and harming).

Answer: We again, completely agree. We changed our abstract and core tip (see page 2), as well as our discussion (see page 19).

3. The authors need to add a paragraph in discussion section regarding the beneficial role of SSRIs use in the negative symptoms of schizophrenia. Although the role of antidepressants use in schizophrenia seems to be limited, there are studies that show improvement of apathy, aboulia and depression when such drugs are used as add on therapy to the standard treatment with antipsychotic medication. This might be another plausible mechanism of the beneficial role of SSRIs in cardiovascular disease in patients with schizophrenia. That is the improvement of negative symptoms and secondary the improvement of life-style and every-day living.

Answer: The Reviewer is correct. This is a very important point. We added a paragraph to our discussion (see page 13) and we added a new reference (see reference # 47).